Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2017 Mar 1;31(3):775. doi: 10.1038/leu.2016.323

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna, T Barbui
PMCID: PMC7609269  PMID: 28248313

Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148

Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.

The authors wish to apologize for any inconvenience caused.

Footnotes

The online version of the original article can be found at 10.1038/leu.2016.148


Articles from Leukemia are provided here courtesy of Nature Publishing Group

RESOURCES